Ponsegromab clinical trials
Also written PF-06946860.
How each study uses ponsegromab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ponsegromab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses ponsegromab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueRecruitingPhase 2/3PfizerNCT06989437Written as ponsegromab
- A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNot yet recruitingPhase 1PfizerNCT07663630Written as ponsegromab
- Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15CompletedPhase 2PfizerNCT05546476Written as ponsegromab
- A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese AdultsCompletedPhase 1PfizerNCT05685264Written as Ponsegromab
- Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaCompletedPhase 1PfizerNCT04803305Written as PF-06946860
- Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.CompletedPhase 1PfizerNCT04299048Written as PF-06946860
- Singe Dose Study of PF- 06946860 in Healthy Adult Japanese ParticipantsCompletedPhase 1PfizerNCT03974776Written as PF-06946860
- Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult SubjectsCompletedPhase 1PfizerNCT03599063Written as PF-06946860
Codes
What other systems call ponsegromab · ClinicalTrials.gg INT016717
- UNII (FDA) GXA6PF0254PONSEGROMABOne source FDA
- NCI Thesaurus C175944PonsegromabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GXA6PF0254 | PONSEGROMAB | One source FDA |
| NCI Thesaurus | C175944 | Ponsegromab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.